These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 32017708)

  • 1. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
    Theivanthiran B; Evans KS; DeVito NC; Plebanek M; Sturdivant M; Wachsmuth LP; Salama AK; Kang Y; Hsu D; Balko JM; Johnson DB; Starr M; Nixon AB; Holtzhausen A; Hanks BA
    J Clin Invest; 2020 May; 130(5):2570-2586. PubMed ID: 32017708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.
    Theivanthiran B; Yarla N; Haykal T; Nguyen YV; Cao L; Ferreira M; Holtzhausen A; Al-Rohil R; Salama AKS; Beasley GM; Plebanek MP; DeVito NC; Hanks BA
    Sci Transl Med; 2022 Nov; 14(672):eabq7019. PubMed ID: 36417489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
    Tengesdal IW; Menon DR; Osborne DG; Neff CP; Powers NE; Gamboni F; Mauro AG; D'Alessandro A; Stefanoni D; Henen MA; Mills TS; De Graaf DM; Azam T; Vogeli B; Palmer BE; Pietras EM; DeGregori J; Tan AC; Joosten LAB; Fujita M; Dinarello CA; Marchetti C
    Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression.
    Tengesdal IW; Dinarello A; Powers NE; Burchill MA; Joosten LAB; Marchetti C; Dinarello CA
    Front Immunol; 2021; 12():661323. PubMed ID: 34531850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
    Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
    Lu F; Zhao Y; Pang Y; Ji M; Sun Y; Wang H; Zou J; Wang Y; Li G; Sun T; Li J; Ma D; Ye J; Ji C
    Cancer Lett; 2021 Jan; 497():178-189. PubMed ID: 33091534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells.
    van Deventer HW; Burgents JE; Wu QP; Woodford RM; Brickey WJ; Allen IC; McElvania-Tekippe E; Serody JS; Ting JP
    Cancer Res; 2010 Dec; 70(24):10161-9. PubMed ID: 21159638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
    Huang F; Gonçalves C; Bartish M; Rémy-Sarrazin J; Issa ME; Cordeiro B; Guo Q; Emond A; Attias M; Yang W; Plourde D; Su J; Gimeno MG; Zhan Y; Galán A; Rzymski T; Mazan M; Masiejczyk M; Faber J; Khoury E; Benoit A; Gagnon N; Dankort D; Journe F; Ghanem GE; Krawczyk CM; Saragovi HU; Piccirillo CA; Sonenberg N; Topisirovic I; Rudd CE; Miller WH; Del Rincón SV
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33690225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDSC-targeting gold nanoparticles enhance PD-1 tumor immunotherapy by inhibiting NLRP3 inflammasomes.
    Zhu Y; Chen P; Hu B; Zhong S; Yan K; Wu Y; Li S; Yang Y; Xu Z; Lu Y; Ouyang Y; Bao H; Gu W; Wen L; Zhang Y
    Biomaterials; 2024 Jun; 307():122533. PubMed ID: 38493671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
    Singh S; Xiao Z; Bavisi K; Roszik J; Melendez BD; Wang Z; Cantwell MJ; Davis RE; Lizee G; Hwu P; Neelapu SS; Overwijk WW; Singh M
    J Immunol; 2021 Apr; 206(8):1966-1975. PubMed ID: 33722878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
    Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
    Front Immunol; 2021; 12():793831. PubMed ID: 34987517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
    Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
    Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
    Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
    J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.